Citatuzumab bogatox
As of the edition of 20 October 2026, Citatuzumab bogatox is an antibody drug conjugate: stopped in 2008; acts on EPCAM.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2008
- Kind
- Antibody drug conjugate
- Registered trials
- 1, 1 stopped early
- Disease areas
- Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EPCAM | Epithelial cell adhesion molecule | P16422 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sesen Bio | Lead sponsor of trials | 2007 to now |